Medtronic plc
MDTAPI behind this page
MDT Q4 2025 request
Playground key active
/api/financials?ticker=MDT&year=2025&quarter=4
Pick an endpoint and run the request.Income Statement
| Metric | Q4 2025 | Q4 2024 | YoY |
|---|---|---|---|
| Revenue | 8,927 | 8,589 | +3.9% |
Show Business Segments breakouts |
|||
| All Other Segments · International | 15 | 32 | -53.1% |
| All Other Segments · Operating Segments | 31 | 57 | -45.6% |
| All Other Segments · US | 17 | 26 | -34.6% |
| Cardiovascular · International | 1,773 | 1,682 | +5.4% |
| Cardiovascular · Operating Segments | 3,336 | 3,129 | +6.6% |
| Cardiovascular · US | 1,562 | 1,448 | +7.9% |
| Diabetes · International | 488 | 436 | +11.9% |
| Diabetes · Operating Segments | 728 | 659 | +10.5% |
| Diabetes · US | 240 | 223 | +7.6% |
| Medical Surgical · International | 1,266 | 1,244 | +1.8% |
| Medical Surgical · Operating Segments | 2,211 | 2,198 | +0.6% |
| Medical Surgical · US | 946 | 954 | -0.8% |
| Neuroscience · International | 838 | 853 | -1.8% |
| Neuroscience · Operating Segments | 2,620 | 2,545 | +2.9% |
| Neuroscience · US | 1,782 | 1,691 | +5.4% |
| Reportable segment net sales · International | 4,366 | 4,215 | +3.6% |
| Reportable segment net sales · Operating Segments | 8,896 | 8,532 | +4.3% |
| Reportable segment net sales · US | 4,531 | 4,317 | +5.0% |
Show Geography breakouts |
|||
| IE | 30 | 27 | +11.1% |
| International | 4,379 | 4,247 | +3.1% |
| Total other countries, excluding Ireland | 8,897 | 8,562 | +3.9% |
| US | 4,547 | 4,343 | +4.7% |
Show — breakouts |
|||
| Revenue | 28,830 | 27,734 | +4.0% |
| Revenue | -4,522 | -4,187 | -8.0% |
| Revenue | 4,350 | 4,219 | +3.1% |
| Revenue | 7,822 | 7,423 | +5.4% |
| Revenue | 1,733 | 1,587 | +9.2% |
| Revenue | -2,124 | -1,930 | -10.1% |
| Revenue | -1,105 | -1,050 | -5.2% |
| Revenue | -1,904 | -1,920 | +0.8% |
| Revenue | 3,748 | 4,009 | -6.5% |
| Revenue | 503 | 492 | +2.2% |
| Revenue | 3,888 | 4,033 | -3.6% |
| Revenue | 5,187 | 4,998 | +3.8% |
| Revenue | 3,097 | 2,938 | +5.4% |
| Revenue | -1,700 | -1,719 | +1.1% |
| Revenue | -692 | -560 | -23.6% |
| Cost of Revenue | 3,147 | 3,044 | +3.4% |
| Research And Development Expense Excluding Acquired In Process Cost | 684 | 675 | +1.3% |
| Selling, General & Administrative | 2,720 | 2,765 | -1.6% |
| Amortization Of Intangible Assets | 564 | 419 | +34.6% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 564 | 419 | +34.6% |
| Restructuring Charges Net Of Restructuring Reversals Including Cost Of Product Sold Impact | 147 | 112 | +31.2% |
| Other Operating Income Expense Net | 15 | 477 | -96.9% |
| Operating Income | 1,436 | 1,053 | +36.4% |
Show Business Segments breakouts |
|||
| Cardiovascular · Operating Segments | 1,307 | 1,176 | +11.1% |
| Diabetes · Operating Segments | 137 | 90 | +52.2% |
| Medical Surgical · Operating Segments | 813 | 838 | -3.0% |
| Neuroscience · Operating Segments | 1,137 | 1,087 | +4.6% |
| Other Segment · Operating Segments | 10 | 2 | +400.0% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 3,395 | 3,192 | +6.4% |
| Other Non-Operating Income (Expense) | 1 | -5 | +120.0% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 1 | -5 | +120.0% |
| Interest Expense | 174 | 202 | -13.9% |
| Income Before Taxes | 1,261 | 855 | +47.5% |
| Income Tax Expense (Benefit) | 199 | 197 | +1.0% |
| Net Income | 1,061 | 660 | +60.8% |
| Net Income Loss Attributable To Noncontrolling Interest | -5 | -5 | 0.0% |
| Net Income | 1,056 | 654 | +61.5% |
| EPS (Basic) | 0.83 | 0.5 | +66.0% |
| EPS (Diluted) | 0.82 | 0.49 | +67.3% |
| Wtd Avg Shares (Basic) | -1.1 | -2.4 | +54.2% |
| Wtd Avg Shares (Diluted) | -0.7 | -2.2 | +68.2% |
| Comprehensive Income | -389 | 794 | -149.0% |
| Interest Income Expense Net | 147 | 168 | -12.5% |
Balance Sheet
| Metric | Q4 2025 | Q4 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 2,218 | 1,284 | +72.7% |
| Short-Term Investments | 6,747 | 6,721 | +0.4% |
| Accounts Receivable | 6,515 | 6,128 | +6.3% |
| Inventory | 5,476 | 5,217 | +5.0% |
| Other Assets Current | 2,858 | 2,584 | +10.6% |
| Total Current Assets | 23,814 | 21,935 | +8.6% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 6,837 | 6,131 | +11.5% |
Show Geography breakouts |
|||
| IE | 291 | 252 | +15.5% |
| Rest of world | 1,414 | 1,286 | +10.0% |
| Total other countries, excluding Ireland | 6,547 | 5,879 | +11.4% |
| US | 5,133 | 4,593 | +11.8% |
| Goodwill | 41,737 | 40,986 | +1.8% |
Show Business Segments breakouts |
|||
| Cardiovascular | 8,017 | 7,966 | +0.6% |
| Diabetes | 2,255 | 2,255 | 0.0% |
| Medical Surgical | 19,748 | 19,121 | +3.3% |
| Neuroscience | 11,716 | 11,644 | +0.6% |
Show Business Acquisition breakouts |
|||
| Series Of Individually Immaterial Business Acquisitions | 108 | 131 | -17.6% |
| Deferred Tax Assets | 4,040 | 3,657 | +10.5% |
| Other Non-Current Assets | 3,584 | 4,047 | -11.4% |
| Total Assets | 91,680 | 89,981 | +1.9% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 296 | 547 | -45.9% |
| Cardiovascular · Operating Segments | 16,548 | 16,128 | +2.6% |
| Diabetes · Operating Segments | 4,136 | 3,996 | +3.5% |
| Medical Surgical · Operating Segments | 33,317 | 33,586 | -0.8% |
| Neuroscience · Operating Segments | 18,476 | 18,270 | +1.1% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 18,906 | 17,455 | +8.3% |
| Operating Segments | 72,476 | 71,980 | +0.7% |
| Operating Lease Right-of-Use Assets | 1,100 | 1,012 | +8.7% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 11,667 | 13,225 | -11.8% |
| Current Liabilities | |||
| Debt Current | 2,874 | 1,092 | +163.2% |
| Accounts Payable | 2,449 | 2,410 | +1.6% |
| Deferred Compensation Liability Current | 2,514 | 2,375 | +5.9% |
| Accrued Income Taxes Current | 1,358 | 1,330 | +2.1% |
| Other Liabilities Current | 3,683 | 3,582 | +2.8% |
| Total Current Liabilities | 12,879 | 10,789 | +19.4% |
| Current Portion of Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| 0.000 percent five-year 2020 senior notes · Senior Notes | 1,142 | — | — |
| 0.250 percent six-year 2019 senior notes · Senior Notes | 1,142 | — | — |
| 2.625 percent three-year 2022 senior notes · Senior Notes | 571 | — | — |
| Non-Current Liabilities | |||
| Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent | 1,158 | 1,101 | +5.2% |
Show Retirement Plan Type breakouts |
|||
| Pension Plans Defined Benefit · Foreign Plan | 289 | 235 | +23.0% |
| Pension Plans Defined Benefit · US | 221 | 230 | -3.9% |
| Accrued Income Taxes Noncurrent | 1,574 | 1,859 | -15.3% |
| Deferred Tax Liabilities | 403 | 515 | -21.7% |
| Other Non-Current Liabilities | 1,769 | 1,365 | +29.6% |
| Total Liabilities | 43,424 | 39,561 | +9.8% |
| Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| 0.375 percent eight-year 2020 senior notes · Senior Notes | 1,142 | 1,070 | +6.7% |
| 0.750 percent twelve-year 2020 senior notes · Senior Notes | 1,142 | 1,070 | +6.7% |
| 1.000 percent twelve-year 2019 senior notes · Senior Notes | 1,142 | 1,070 | +6.7% |
| 1.125 percent eight-year 2019 senior notes · Senior Notes | 1,714 | 1,606 | +6.7% |
| 1.375 percent twenty-year 2020 senior notes · Senior Notes | 1,142 | 1,070 | +6.7% |
| 1.500 percent twenty-year 2019 senior notes · Senior Notes | 1,142 | 1,070 | +6.7% |
| 1.625 percent thirty-year 2020 senior notes · Senior Notes | 1,142 | 1,070 | +6.7% |
| 1.625 percent twelve-year 2019 senior notes · Senior Notes | 1,142 | 1,070 | +6.7% |
| 1.750 percent thirty-year 2019 senior notes · Senior Notes | 1,142 | 1,070 | +6.7% |
| 2.250 percent twenty-year 2019 senior notes · Senior Notes | 1,142 | 1,070 | +6.7% |
| 3.000 percent six-year 2022 senior notes · Senior Notes | 1,142 | 1,070 | +6.7% |
| 3.125 percent nine-year 2022 senior notes · Senior Notes | 1,142 | 1,070 | +6.7% |
| 3.375 percent twelve-year 2022 senior notes · Senior Notes | 1,142 | 1,070 | +6.7% |
| 3.650 percent five-year 2024 senior notes · Senior Notes | 971 | — | — |
| 3.875 percent twelve-year 2024 senior notes · Senior Notes | 971 | — | — |
| 4.000 percent thirty-year 2013 senior notes · Senior Notes | 305 | 305 | 0.0% |
| 4.150 percent nineteen-year 2024 senior notes · Senior Notes | 685 | — | — |
| 4.150 percent twenty-nine-year 2024 senior notes · Senior Notes | 800 | — | — |
| 4.250 percent five-year 2023 senior notes · Senior Notes | 1,000 | 1,000 | 0.0% |
| 4.375 percent twenty-year 2015 senior notes · Senior Notes | 1,932 | 1,932 | 0.0% |
| 4.500 percent ten-year 2023 senior notes · Senior Notes | 1,000 | 1,000 | 0.0% |
| 4.500 percent thirty-year 2012 senior notes · Senior Notes | 105 | 105 | 0.0% |
| 4.625 percent thirty-year 2014 senior notes · Senior Notes | 127 | 127 | 0.0% |
| 4.625 percent thirty-year 2015 senior notes · Senior Notes | 1,813 | 1,813 | 0.0% |
| 5.550 percent thirty-year 2010 senior notes · Senior Notes | 224 | 224 | 0.0% |
| 6.500 percent thirty-year 2009 senior notes · Senior Notes | 158 | 158 | 0.0% |
| 6.550 percent thirty-year 2007 CIFSA senior notes · Senior Notes | 253 | 253 | 0.0% |
| Operating Lease Liabilities | 918 | 840 | +9.3% |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 25,642 | 23,932 | +7.1% |
| Stockholders' Equity | |||
| Additional Paid-In Capital | 20,833 | 23,129 | -9.9% |
| Retained Earnings | 31,476 | 30,403 | +3.5% |
| Accumulated Other Comprehensive Income | -4,284 | -3,318 | -29.1% |
| Total Stockholders' Equity | 48,024 | 50,214 | -4.4% |
| Minority Interest | 232 | 206 | +12.6% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 48,256 | 50,420 | -4.3% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -640 | -529 | -21.0% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -149 | 229 | -165.1% |
| Accumulated Net Unrealized Investment Gain Loss | -63 | -212 | +70.3% |
| Accumulated Other Comprehensive Income | -4,284 | -3,318 | -29.1% |
| Accumulated Translation Adjustment | -2,835 | -3,686 | +23.1% |
| Additional Paid In Capital | 20,833 | 23,129 | -9.9% |
| Aoci Derivative Qualifying As Hedge Excluded Component Parent | -597 | 878 | -168.0% |
| Noncontrolling Interest | 232 | 206 | +12.6% |
| Parent | 48,024 | 50,214 | -4.4% |
| Retained Earnings | 31,476 | 30,403 | +3.5% |
| Total Liabilities & Equity | 91,680 | 89,981 | +1.9% |
Cash Flow Statement
| Metric | YTD Q4 2025 | YTD Q4 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 840 | 654 | +28.4% |
| Provision For Doubtful Accounts | 27 | 28 | -3.6% |
| Deferred Income Taxes And Tax Credits | -235 | -258 | +8.9% |
| Stock-Based Compensation | 89 | 90 | -1.1% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 89 | 90 | -1.1% |
| Other Non-Cash Items | 296 | 308 | -3.9% |
| Increase Decrease In Accounts And Notes Receivable | -249 | -251 | +0.8% |
| Change in Inventory | 186 | 391 | -52.4% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | 366 | 644 | -43.2% |
| Increase Decrease In Other Operating Capital Net | 147 | 140 | +5.0% |
| Net Cash from Operations | 2,528 | 2,777 | -9.0% |
| Investing Activities | |||
| Payments To Acquire Businesses Net Of Cash Acquired | 0 | -137 | +100.0% |
| Capital Expenditures | -459 | -426 | -7.7% |
| Payments To Acquire Investments | -2,133 | -2,326 | +8.3% |
| Proceeds From Sale Maturity And Collections Of Investments | 2,240 | 2,299 | -2.6% |
| Other Investing Activities | -138 | -106 | -30.2% |
| Net Cash from Investing | -490 | -696 | +29.6% |
| Financing Activities | |||
| Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less | 0 | 63 | -100.0% |
| Payments Of Dividends Common Stock | -897 | -913 | +1.8% |
| Proceeds From Issuance Or Sale Of Equity | 108 | 78 | +38.5% |
| Share Repurchases | -274 | -1,628 | +83.2% |
| Proceeds From Payments For Other Financing Activities | -280 | 41 | -782.9% |
| Net Cash from Financing | -1,343 | -2,359 | +43.1% |
| Supplemental | |||
| Income Taxes Paid | 304 | 219 | +38.8% |
| Interest Paid | 195 | 258 | -24.4% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 283 | -60 | +571.7% |
| Net Change in Cash | 978 | -339 | +388.5% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 2,218 | 1,284 | +72.7% |
Values in millions USD. Source: SEC EDGAR 10-K filing.